• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Current prospects and future challenges for nasal vaccine delivery

tetano

Editor, Senior Moderator
Hum Vaccin Immunother. 2016 Dec 9:1-12. [Epub ahead of print]
[h=1]Current prospects and future challenges for nasal vaccine delivery.[/h] Yusuf H[SUP]1[/SUP], Kett V[SUP]2[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Nasal delivery offers many benefits over traditional approaches to vaccine administration. These include ease of administration without needles that reduces issues associated with needlestick injuries and disposal. Additionally, this route offers easy access to a key part of the immune system that can stimulate other mucosal sites throughout the body. Increased acceptance of nasal vaccine products in both adults and children has led to a burgeoning pipeline of nasal delivery technology. Key challenges and opportunities for the future will include translating in vivo data to clinical outcomes. Particular focus should be brought to designing delivery strategies that take into account the broad range of diseases, populations and healthcare delivery settings that stand to benefit from this unique mucosal route.


[h=4]KEYWORDS:[/h] influenza; mucosal; nasal; needle-free; vaccine

PMID: 27936348 DOI: 10.1080/21645515.2016.1239668
[PubMed - as supplied by publisher]
 
Back
Top Bottom